On November 15, 2021, Nanjing Vazyme Biotech Co., Ltd. (Vazyme) went public on 
the STAR MARKET of the Shanghai Stock Exchange under the stock code 688105. 

Founded in Nanjing in 2012, Vazyme develops technologies and products related 
to functional proteins including enzymes, antigens and antibodies as well as 
organic polymer materials. Relying on its proprietary critical generic 
technology platform, the company has successively entered business areas 
including biological research, in vitro diagnosis and biomedicine. Vazyme is 
one of the few innovative R&D companies with both independent and controllable 
upstream technology development and final product manufacturing capabilities in 
China. The company owns more than 200 kinds of genetic engineering recombinases 
and 1,000 kinds of high-performance antigens and monoclonal antibodies. In 
addition, Vazyme has over 500 final products that have wide applications in 
scientific research, high-throughput sequencing, in vitro diagnosis, 
pharmaceutical and vaccine development as well as animal quarantine, among 
other fields. 

Backed by many years of experience in the molecular biological reagent segment, 
Vazyme has strong R&D and product iteration capabilities, a perfected technical 
system and a well-established marketing network. Looking ahead, the 
publicly-listed company plans to accelerate its roadmap for an expanded 
presence in global markets, with the expectation of contributing to the ongoing 
development of the world's biotechnology sector. 

At the ceremony celebrating the firm's success at listing on the Shanghai Stock 
Exchange, Vazyme chairman and founder Cao Lin said, "Today's listing is of 
great significance to Vazyme. We have worked on obtaining this listing for 
nearly 10 years, in this period we made our full efforts and experienced all 
kinds of hardships. Vazyme will strictly comply with each and every one of the 
requirements and rules for listed companies, constantly enhance our management, 
communicate regularly with investors and maintain the transparency of our 
company, as part of our mission to give back to society and the shareholders by 
way of sustained growth and better performance." 

SOURCE: Vazyme

Image Attachments Links:

   Link: https://iop.asianetnews.net/view-attachment?attach-id=407513

   Caption: Vazyme goes public on Shanghai Stock Exchange today